Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01034631 · ClinicalTrials.gov registry record · Phase 1

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

A Phase 1 study of Renal Cell Carcinoma, sponsored by Hoosier Cancer Research Network.

Completed
Registry status
Phase 1
Development phase
154
Enrollment target
20
Study locations

NCT01034631 is a Phase 1 study of Renal Cell Carcinoma that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 154 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01034631, a Phase 1 study of Renal Cell Carcinoma, has completed, sponsored by Hoosier Cancer Research Network.

COMPLETED
Registry status
Phase 1
Development phase
154 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Everolimus
  • DRUG BNC105P

Study Locations (20)

California

  • Providence Health System: Roy and Patricia Disney Family Cancer Center - Burbank
  • Compassionate Cancer Care Medical Group, Inc. - Corona
  • Compassionate Cancer Care Medical Group - Corona
  • City of Hope - Duarte
  • Robert A. Moss, M.D., FACP, Inc. - Fountain Valley
  • California Cancer Associates for Research and Excellence - Fresno
  • Marin Specialty Care - Greenbrae
  • Good Samaritan Hospital - Los Angeles
  • UCLA Med - Hematology & Oncology - Los Angeles
  • Compassionate Cancer Care Medical Group - Riverside
  • American Institute of Research - Whittier

Florida

  • Cancer Care Centers of Florida: Brooksville - Brooksville
  • Broward Oncology Associates - Fort Lauderdale
  • University of Florida, Shands Cancer Center - Gainesville
  • Cancer Specialists of North Florida - Jacksonville
  • Advanced Pharma CR, LLC - Miami

Colorado

  • Centura Health Research Center - Denver
  • Western Oncology & Hematology - Golden

Alabama

  • Northwest Alabama Cancer Center - Muscle Shoals

Arkansas

  • Genesis Cancer Center - Hot Springs

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2010-01
Est. Completion 2016-12
Phase Phase 1

Sponsor

Hoosier Cancer Research Network

26 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01034631

The ClinicalTrials.gov registry entry for NCT01034631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (36% lower). The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.

NCT01034631 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT01034631 about?

NCT01034631 is a clinical study titled "BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma". The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.

What is the current status of trial NCT01034631?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2010-01. Estimated completion is 2016-12.

What conditions does trial NCT01034631 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT01034631?

The interventions under investigation include: Everolimus (DRUG), BNC105P (DRUG).

Who is sponsoring clinical trial NCT01034631?

This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01034631 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.